

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following is true regarding the Phase III COMBI-AD study evaluating adjuvant dabrafenib/trametinib compared to placebo for patients with Stage III melanoma and BRAF mutations?
  - The study enrolled patients with completely resected Stage III disease
  - The study failed to meet its primary endpoint of relapse-free survival
  - Fewer than 5% of patients discontinued treatment due to drug-related or treatment-related toxicity
- The Phase III CheckMate 238 study investigating adjuvant nivolumab versus ipilimumab for resected Stage III/IV melanoma demonstrated \_\_\_\_\_.
  - A significantly longer recurrence-free survival in favor of nivolumab
  - A lower rate of Grade 3/4 adverse events with ipilimumab
  - Both a and b
- Which of the following statements is true regarding Merkel cell carcinoma?
  - It progresses rapidly
  - It often metastasizes to the pancreas
  - Only the virus-associated form responds to anti-PD-1/PD-L1 antibodies
  - All of the above
  - Both a and b
- Patients with melanoma treated with the combination of vemurafenib/cobimetinib are more likely to experience \_\_\_\_\_ than those receiving the combination of dabrafenib/trametinib or encorafenib/binimetinib.
  - Palmar-plantar erythrodysesthesia
  - Photosensitivity
- The target of the monoclonal antibody relatlimab is \_\_\_\_\_.
  - PD-1
  - CTLA-4
  - LAG-3
- The Phase I/II ECHO-202/KEYNOTE-037 trial of epacadostat in combination with pembrolizumab for patients with advanced melanoma demonstrated \_\_\_\_\_.
  - An overall response rate of about 60%
  - Median progression-free survival of about 1 year
  - Both a and b
- The Phase III ONTRAC study demonstrated that the use of nicotinamide was effective in reducing the rates of which of the following skin cancers?
  - BCC
  - Melanoma
  - Squamous cell carcinoma
  - All of the above
  - Both a and c
  - Both b and c
- The hedgehog inhibitor sonidegib when used in the treatment of BCC \_\_\_\_\_.
  - Can cause changes in taste, muscle spasms and hair loss
  - Can achieve response after the reinitiation of therapy following a treatment holiday to mitigate toxicities
  - Is not as well tolerated as vismodegib
  - All of the above
  - Both a and b
  - Both a and c
- Patients with metastatic uveal melanoma typically have \_\_\_\_\_.
  - Durable responses to single-agent anti-PD-1/PD-L1 antibody therapy
  - Mutations in G proteins
  - Both a and b
- Squamous cell carcinoma of the skin is associated with long-term unprotected sun exposure, and metastasis to distant sites occurs only in a small percent of patients.
  - True
  - False